AvidBiotics Taps Nature for Two Ways To Fight Lethal Microbes
By: Bernadette Tansey | Source: Xconomy
The trillions of microbes that live inside the human gastrointestinal tract are suspected of playing a role in disorders as varied as obesity, asthma, and diabetes. Scores of scientists are studying such possibilities at biomedical research companies and in collaborations such as NIH’s Human Microbiome Project.
But can these diseases be caused by a single rogue germ in the gut, or do the illnesses take hold because the overall balance of a person’s microbial ecosystem has gone awry?
Read or purchase full article from: Xconomy
Pylum Biosciences Collaborates on Research Published in the Journal Nature
AvidBiotics’ Scientists Co-author Publication in Science Translational Medicine Describing A New Class of Targeted Antibacterial Agents for Clostridium difficile
Study Published in mBio Shows that Avidocin™ Proteins Prevent Clostridium Difficile Infection in Mice without Harming Protective Gut Bacteria
AvidBiotics Granted U.S. Patent for Bactericidal Proteins that Selectively Kill C. Difficile
AvidBiotics Awarded SBIR Grant for Avidocin™ Antibacterial Proteins Against Clostridium difficile